| pubmed-article:21629651 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21629651 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:21629651 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:21629651 | lifeskim:mentions | umls-concept:C0024535 | lld:lifeskim |
| pubmed-article:21629651 | lifeskim:mentions | umls-concept:C0577559 | lld:lifeskim |
| pubmed-article:21629651 | lifeskim:mentions | umls-concept:C2587213 | lld:lifeskim |
| pubmed-article:21629651 | lifeskim:mentions | umls-concept:C1880177 | lld:lifeskim |
| pubmed-article:21629651 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:21629651 | pubmed:dateCreated | 2011-6-1 | lld:pubmed |
| pubmed-article:21629651 | pubmed:abstractText | Mass treatment as a means to reducing P. falciparum malaria transmission was used during the first global malaria eradication campaign and is increasingly being considered for current control programmes. We used a previously developed mathematical transmission model to explore both the short and long-term impact of possible mass treatment strategies in different scenarios of endemic transmission. Mass treatment is predicted to provide a longer-term benefit in areas with lower malaria transmission, with reduced transmission levels for at least 2 years after mass treatment is ended in a scenario where the baseline slide-prevalence is 5%, compared to less than one year in a scenario with baseline slide-prevalence at 50%. However, repeated annual mass treatment at 80% coverage could achieve around 25% reduction in infectious bites in moderate-to-high transmission settings if sustained. Using vector control could reduce transmission to levels at which mass treatment has a longer-term impact. In a limited number of settings (which have isolated transmission in small populations of 1000-10,000 with low-to-medium levels of baseline transmission) we find that five closely spaced rounds of mass treatment combined with vector control could make at least temporary elimination a feasible goal. We also estimate the effects of using gametocytocidal treatments such as primaquine and of restricting treatment to parasite-positive individuals. In conclusion, mass treatment needs to be repeated or combined with other interventions for long-term impact in many endemic settings. The benefits of mass treatment need to be carefully weighed against the risks of increasing drug selection pressure. | lld:pubmed |
| pubmed-article:21629651 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21629651 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21629651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21629651 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21629651 | pubmed:issn | 1932-6203 | lld:pubmed |
| pubmed-article:21629651 | pubmed:author | pubmed-author:KleinschmidtI... | lld:pubmed |
| pubmed-article:21629651 | pubmed:author | pubmed-author:WhiteMichael... | lld:pubmed |
| pubmed-article:21629651 | pubmed:author | pubmed-author:GhaniAzra CAC | lld:pubmed |
| pubmed-article:21629651 | pubmed:author | pubmed-author:DrakeleyChris... | lld:pubmed |
| pubmed-article:21629651 | pubmed:author | pubmed-author:BousemaTeunT | lld:pubmed |
| pubmed-article:21629651 | pubmed:author | pubmed-author:Hollingsworth... | lld:pubmed |
| pubmed-article:21629651 | pubmed:author | pubmed-author:ChurcherThoma... | lld:pubmed |
| pubmed-article:21629651 | pubmed:author | pubmed-author:OkellLucy CLC | lld:pubmed |
| pubmed-article:21629651 | pubmed:author | pubmed-author:GriffinJamie... | lld:pubmed |
| pubmed-article:21629651 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21629651 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:21629651 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21629651 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21629651 | pubmed:pagination | e20179 | lld:pubmed |
| pubmed-article:21629651 | pubmed:meshHeading | pubmed-meshheading:21629651... | lld:pubmed |
| pubmed-article:21629651 | pubmed:meshHeading | pubmed-meshheading:21629651... | lld:pubmed |
| pubmed-article:21629651 | pubmed:meshHeading | pubmed-meshheading:21629651... | lld:pubmed |
| pubmed-article:21629651 | pubmed:meshHeading | pubmed-meshheading:21629651... | lld:pubmed |
| pubmed-article:21629651 | pubmed:meshHeading | pubmed-meshheading:21629651... | lld:pubmed |
| pubmed-article:21629651 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21629651 | pubmed:articleTitle | The potential contribution of mass treatment to the control of Plasmodium falciparum malaria. | lld:pubmed |
| pubmed-article:21629651 | pubmed:affiliation | Department of Infectious Disease Epidemiology, MRC Centre for Outbreak Analysis and Modeling, Imperial College London, London, United Kingdom. l.okell@imperial.ac.uk | lld:pubmed |
| pubmed-article:21629651 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21629651 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
